Clinical Trial Update: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating durvalumab alone or with chemotherapy for advanced non-small cell lung cancer (NSCLC) is active/not recruiting with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Non-small Cell Lung Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Carcinoma NSCLC | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-26